Analyst Ratings For Coherus Biosciences Inc (NASDAQ:CHRS)
Today, HC Wainwright set its price target on Coherus Biosciences Inc (NASDAQ:CHRS) to $28.00 per share.
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Coherus Biosciences Inc (NASDAQ:CHRS) is Buy with a consensus target price of $23.75 per share, a potential 43.07% upside.
Some recent analyst ratings include
- 9/25/2018-Coherus Biosciences Inc (NASDAQ:CHRS) had its Buy rating reiterated by Maxim Group with a $25.00 price target
- 9/27/2017-Coherus Biosciences Inc (NASDAQ:CHRS) had its Outperform rating reiterated by Credit Suisse Group with a $17.00 price target
- 9/8/2017-Coherus Biosciences Inc (NASDAQ:CHRS) had its Outperform rating reiterated by Cowen with a $45.00 price target
- 8/8/2017-Coherus Biosciences Inc (NASDAQ:CHRS) had its Overweight ➝ Overweight rating reiterated by JPMorgan Chase & Co. with a $25.00 price target
Recent Insider Trading Activity For Coherus Biosciences Inc (NASDAQ:CHRS)
Coherus Biosciences Inc (NASDAQ:CHRS) has insider ownership of 19.57% and institutional ownership of 91.31%.
- On 9/10/2018 Barbara K Finck, Insider, sold 1,760 with an average share price of $18.58 per share and the total transaction amounting to $32,700.80.
- On 8/29/2018 James Healy, Director, sold 25,000 with an average share price of $20.50 per share and the total transaction amounting to $512,500.00.
- On 8/13/2018 Barbara K Finck, Insider, sold 1,760 with an average share price of $19.02 per share and the total transaction amounting to $33,475.20.
- On 7/23/2018 Jean-Frederic Viret, CFO, sold 9,291 with an average share price of $18.56 per share and the total transaction amounting to $172,440.96.
- On 7/10/2018 Barbara K Finck, Insider, sold 1,760 with an average share price of $15.01 per share and the total transaction amounting to $26,417.60.
- On 6/18/2018 Barbara K. Finck, Insider, sold 1,760 with an average share price of $15.00 per share and the total transaction amounting to $26,400.00.
- On 5/16/2018 Dennis M Lanfear, Insider, sold 20,984 with an average share price of $16.26 per share and the total transaction amounting to $341,199.84.
About Coherus Biosciences Inc (NASDAQ:CHRS)
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Recent Trading Activity for Coherus Biosciences Inc (NASDAQ:CHRS)
Shares of Coherus Biosciences Inc closed the previous trading session at 16,60 +0,50 3,11 % with 16 shares trading hands.